CD274 and neoplasm: These results are similar to the findings of Moreno et al.39, where the authors showed that a quadruplet combination of a BRAFi, MEKi, either α-PD-1 or α-PDL-1 and either α-4-1BB or α-OX-40 significantly delayed tumor growth in BRAF mutant melanoma models.